Is Alzheimer's disease a synaptic disorder?
BACKGROUND
In Alzheimer's disease (AD), the common symptom is loss of memory. Learning and memory are associated with amoeboid movements of synaptic endings. Docosahexaenoic acid (DHA) is a major lipid constituent of synaptic end sites. Minor changes in the fluidity of phospholipidic membranes have a dramatic impact on the function of synapses, where membrane fluidity may influence the neurotransmitter receptor activity.


METHODS
Studies pertaining to the role of DHA as a neuroprotective agent was reviewed.


RESULTS
Here we will show a conceptual framework for the role of DHA in the prevention of AD. The DHA content has been shown to be decreased in the brain and plasma of patients affected by AD. Aspirin triggers the generation of DHA-derived mediators that are themselves neuroprotective.


CONCLUSIONS
Adequate dietary intakes of the neuroprotective DHA (and aspirin?) may slow down the progression of AD. An essential reserve of synapses from early development is needed.
Pomponi
Massimiliano
M
Department of Psychiatry, School of Medicine A. Gemelli, Largo F. Vito 1, Rome, Italy. m.pomponi@rm.unicatt.it
Bria
Pietro
P
Pomponi
Massimo
M
D000544:Alzheimer Disease / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D004281:Docosahexaenoic Acids / Q000378:metabolism / Q000627:therapeutic use; D015118:Eicosapentaenoic Acid / Q000378:metabolism / Q000627:therapeutic use; D005247:Feeding Behavior; D006801:Humans; D013569:Synapses / Q000378:metabolism / Q000502:physiology*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid; D001241:Aspirin